Garrett M. Frampton

Garrett M. Frampton

Auto-generated profile, based on publicly available information

Garrett M. Frampton

Computational Discovery, Foundation Medicine, Inc., Cambridge, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MCMenno P. Creyghton
Menno P. Creyghton
ACAlbert W. Cheng
Albert W. Cheng
GWG. Grant Welstead
G. Grant Welstead
TKTristan Kooistra
Tristan Kooistra
BCBryce W. Carey
Bryce W. Carey
RJRudolf Jaenisch
Rudolf Jaenisch
Developmental programs are controlled by transcription factors and chromatin regulators, which maintain specific gene expression programs through epigenetic modification of the genome. These regulatory events at enhancers contribute to the specific gene expression programs that determine cell state and the potential for differentiation into new cell types. Although enhancer elements are known to be associated with certain histone modifications and transcription factors, the relationship of these modifications to gene expression and developmental state has not been clearly defined. Here we interrogate the epigenetic landscape of enhancer elements in embryonic stem cells and several adult tissues in the mouse. We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements containing H3K4me1 alone. This indicates that the amount of actively used enhancers is lower than previously anticipated. Furthermore, poised enhancer networks provide clues to unrealized developmental programs. Finally, we show that enhancers are reset during nuclear reprogramming.

1 May 2016 in The Lancet
Verified
Journal Article
Closed access
JRJonathan E Rosenberg
Jonathan E Rosenberg
JHJean Hoffman-Censits
Jean Hoffman-Censits
TPTom Powles
Tom Powles
MHMichiel S van der Heijden
Michiel S van der Heijden
ABArjun V Balar
Arjun V Balar
RDRobert Dreicer
Robert Dreicer

19 April 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
ZCZachary R. Chalmers
Zachary R. Chalmers
CCCaitlin F. Connelly
Caitlin F. Connelly
DFDavid Fabrizio
David Fabrizio
LGLaurie Gay
Laurie Gay
SASiraj M. Ali
Siraj M. Ali
GFGarrett M. Frampton
Garrett M. Frampton
High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with high TMB has not been well characterized in the majority of cancer types. In this study, we compare TMB measured by a targeted comprehensive genomic profiling (CGP) assay to TMB measured by exome sequencing and simulate the expected variance in TMB when sequencing less than the whole exome. We then describe the distribution of TMB across a diverse cohort of 100,000 cancer cases and test for association between somatic alterations and TMB in over 100 tumor types. We demonstrate that measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly. We find that a subset of patients exhibits high TMB across almost all types of cancer, including many rare tumor types, and characterize the relationship between high TMB and microsatellite instability status. We find that TMB increases significantly with age, showing a 2.4-fold difference between age 10 and age 90 years. Finally, we investigate the molecular basis of TMB and identify genes and mutations associated with TMB level. We identify a cluster of somatic mutations in the promoter of the gene PMS2, which occur in 10% of skin cancers and are highly associated with increased TMB. These results show that a CGP assay targeting ~1.1 Mb of coding genome can accurately assess TMB compared with sequencing the whole exome. Using this method, we find that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy. Finally, we identify novel, recurrent promoter mutations in PMS2, which may be another example of regulatory mutations contributing to tumorigenesis.

1 August 2008 in Cell
Verified
Journal Article
Closed access
AMAlexander Marson
Alexander Marson
SLStuart S. Levine
Stuart S. Levine
MCMegan F. Cole
Megan F. Cole
GFGarrett M. Frampton
Garrett M. Frampton
TBTobias Brambrink
Tobias Brambrink
RYRichard A. Young
Richard A. Young

1 August 2015 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
LBLauren A. Byers
Lauren A. Byers
LDLixia Diao
Lixia Diao
VPVassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou
PTPan Tong
Pan Tong
JHJohn V. Heymach
John V. Heymach
The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung adenocarcinoma are poorly characterized. We performed an integrative analysis of genomic, transcriptomic, and proteomic data from early-stage and chemorefractory lung adenocarcinoma and identified three robust subsets of KRAS-mutant lung adenocarcinoma dominated, respectively, by co-occurring genetic events in STK11/LKB1 (the KL subgroup), TP53 (KP), and CDKN2A/B inactivation coupled with low expression of the NKX2-1 (TTF1) transcription factor (KC). We further revealed biologically and therapeutically relevant differences between the subgroups. KC tumors frequently exhibited mucinous histology and suppressed mTORC1 signaling. KL tumors had high rates of KEAP1 mutational inactivation and expressed lower levels of immune markers, including PD-L1. KP tumors demonstrated higher levels of somatic mutations, inflammatory markers, immune checkpoint effector molecules, and improved relapse-free survival. Differences in drug sensitivity patterns were also observed; notably, KL cells showed increased vulnerability to HSP90-inhibitor therapy. This work provides evidence that co-occurring genomic alterations identify subgroups of KRAS-mutant lung adenocarcinoma with distinct biology and therapeutic vulnerabilities. Significance: Co-occurring genetic alterations in STK11/LKB1, TP53, and CDKN2A/B—the latter coupled with low TTF1 expression—define three major subgroups of KRAS-mutant lung adenocarcinoma with distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities. Cancer Discov; 5(8); 860–77. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 783

1 January 2011 in Cell
Verified
Journal Article
Closed access
NNNoa Novershtern
Noa Novershtern
ASAravind Subramanian
Aravind Subramanian
LLLee N. Lawton
Lee N. Lawton
RMRaymond H. Mak
Raymond H. Mak
WHW. Nicholas Haining
W. Nicholas Haining
BEBenjamin L. Ebert
Benjamin L. Ebert